Merck and Co. Inc. isn’t exactly ditching its hepatitis C virus (HCV) NS5B polymerase inhibitor, known as uprifosbuvir (MK-3682/3682B) – for now, at least. Enrollment continues in ongoing trials of uprifosbuvir – in development in triple- and double-combination HCV regimens, company spokeswoman Lainie Keller told BioWorld Today.